Research publications

CHRU’s scientific output and contribution

DEPT - CHRU's Quality Assurance department ensures compliance with sponsor, regulatory and ethical requirements

Research publications

CHRU scientists widely published in high impact journals

The Clinical HIV Research Unit (CHRU) has made significant contributions to infectious diseases research since it was founded in 2001. Successful implementation of its research programme has seen publication output in high impact journals grow year-on-year.

Publications

CHRU’s scientific output and contribution

CHRU scientists widely published in high impact journals

CHRU Publications

Building sustainable clinical trial sites in Sub-Saharan Africa through networking, infrastructure improvement, training and conducting clinical studies: The PanACEA approach

The lived experiences of Tuberculosis survivors during the COVID-19 pandemic and government lockdown in South Africa: a qualitative analysis

Performance of spirometry assessment at TB diagnosis

Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis

Contemporary Issues in Women's Health

Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis

Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis

Adverse Pregnancy Outcomes among HIV-infected Women Taking Isoniazid Preventive Therapy During the First Trimester

Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis

Rifapentine with and without moxifloxacin for pulmonary tuberculosis in people with HIV

Tuberculosis and Sexual and Reproductive Health of Women in Four African Countries

Tuberculosis and Sexual and Reproductive Health of Women in Four African Countries

Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study

Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis

Applying machine learning and predictive modeling to retention and viral suppression in South African HIV treatment cohorts

Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 InfectionC

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study

Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis

infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

Treatment of Rifampicin-Resistant Tuberculosis Disease and Infection in Children: Key Updates, Challenges and Opportunities

Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled tria

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

Guiding equitable prioritisation of COVID-19 vaccine distribution and strategic deployment in South Africa to enhance effectiveness and access to vulnerable communities and prevent waste

Mitigation strategies to safely conduct HIV treatment research in the context of COVID-19

Hepatitis B surface antigen and hepatitis B RNA changes in HIV/hepatitis B virus co-infected participants receiving hepatitis B virus-active antiretroviral

Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis

Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study

Effectiveness of GenoType MTBDRsl in excluding TB drug resistance in a clinical trial

Resistance to Mycobacterium tuberculosis Infection Among Household Contacts: A Multinational Study

Operational characteristics of 30 lateral flow immunoassays used to identify COVID-19 immune response

Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study

QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial

Sexually transmitted infections among HIV serodiscordant partners: A secondary analysis of HIV Prevention Trial Network 052

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

The Role of Remdesivir in South Africa: Preventing COVID-19 Deaths Through Increasing Intensive Care Unit Capacity

Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.

Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine

Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial

Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results

Mapping the cervical cancer screening cascade among women living with HIV in Johannesburg, South Africa

Adaptation of WHO's generic tuberculosis patient cost instrument for a longitudinal study in Africa

Human Papillomavirus Vaccination Prior to Loop Electroexcision Procedure Does Not Prevent Recurrent Cervical High-grade Squamous Intraepithelial Lesions in Women Living With Human Immunodeficiency Virus

Year

Building sustainable clinical trial sites in Sub-Saharan Africa through networking, infrastructure improvement, training and conducting clinical studies: The PanACEA approach

Predictive Value of Serum Biomarkers for Response of Limited-Stage AIDS-Associated Kaposi Sarcoma to Antiretroviral Therapy With or Without Concomitant Chemotherapy in Resource-Limited Settings

"When you get the HPV vaccine, it will prevent cervical cancer; it will act as a shield": adolescent girls' knowledge and perceptions regarding the human papillomavirus vaccine in Zambia

The lived experiences of Tuberculosis survivors during the COVID-19 pandemic and government lockdown in South Africa: a qualitative analysis

Performance of spirometry assessment at TB diagnosis

Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis

Contemporary Issues in Women's Health

Implementation Strategies Used to Increase Human Papillomavirus Vaccination Uptake by Adolescent Girls in Sub-Saharan Africa: A Scoping Review

Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis

Effect of the relationship between anaemia and systemic inflammation on the risk of incident tuberculosis and death in people with advanced HIV: a sub-analysis of the REMEMBER trial

Pharmacokinetics of dose-adjusted levonorgestrel emergency contraception combined with efavirenz-based antiretroviral therapy or rifampicin-containing tuberculosis regimens

An Evaluation of the Cost of Human Papilloma Virus (HPV) Vaccine Delivery In Zambia

A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials

Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis

Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement

Correlates of Parental Consent to Human Papillomavirus Vaccine Uptake by Their Adolescent Daughters in ZAMBIA: Application of the Health Belief Model

A cohort study of post-COVID-19 condition across the Beta, Delta, and Omicron waves in South Africa: 6-month follow-up of hospitalized and nonhospitalized participants

Factors associated with prevalent Mycobacterium tuberculosis infection and disease among adolescents and adults exposed to rifampin-resistant tuberculosis in the household

Adverse Pregnancy Outcomes among HIV-infected Women Taking Isoniazid Preventive Therapy During the First Trimester

Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)

Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised

Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis

Antiretroviral initiation at ≥800 CD4+ cells/ mm 3 associated with lower HIV reservoir size

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial

Treatment outcomes and costs of a simplified antiretroviral treatment strategy for hepatitis C among Hepatitis C Virus and Human Immuno deficiency Virus co-infected patients in Ukraine